Search

everythinglearnresearchcommunity

for

Search:↓

The user used oral finasteride, topical minoxidil foam, a derma roller, keto shampoo, Hims thick fix shampoo, hair dye, and rosemary oil for hair restoration. They reported no side effects and noted significant improvement, especially in the hairline.

A recent publication suggests that the flavonoids eriocitrin and silymarin may be more effective than finasteride in binding to the enzyme responsible for hair loss. People in the conversation are skeptical about the effectiveness and safety of these flavonoids until tested on humans, and some discuss their personal experiences with other treatments.

The conversation humorously speculates on whether an elderly man's good hairline is due to finasteride, dutasteride, or genetics. It also discusses the role of DHT and genetics in hair loss.

A 56-year-old user shared progress pictures from January to June 2024, detailing their hair loss treatment journey. They used Nanoxidil, oral Minoxidil, Finasteride (later switched to Dutasteride), RU58841, and LLLT therapy, noting slow but visible improvements.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.

User shared progress with RU 58841, Minox, and Dutasteride 3 times a week for hair loss. Others noticed improvements and expect great gains over the next year.

RU58841 users discuss seeing results in a few months. Minoxidil and finasteride are also mentioned as treatments.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

User doubts oral minoxidil's effectiveness after a month of use and shedding. Few people provide photo evidence of success, and some combine it with other treatments, making it hard to determine its effectiveness alone.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

Minoxidil may cause facial aging or wrinkles, though opinions vary. Some users report side effects like dark circles and facial bloating, while others attribute changes to genetics or other factors.

Pyrilutamide is officially available for purchase, and users suggest Fluridil as an alternative topical anti-androgen. Some users report positive results with pyrilutamide from Koshine.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.